Bridgewater, New Jersey (USA), August 18, 2015 – Amneal Pharmaceuticals LLC (www.amneal.com) today announced the launch of aripiprazole oral solution in 1 mg/mL strength, allowing prescriber to continue writing for the recently discontinued reference brand.
The Amneal generic—one of the first liquid forms on the market—is an AA-rated, therapeutic equivalent to the discontinued Abilify® Oral Solution. It is now shipping in 150 mL (5 fl oz) bottles through wholesalers, distributors and directly to the trade. “Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require,” explains Jim Luce, Amneal Executive Vice President of Sales & Marketing. “It’s a product that would otherwise be unavailable if not for the generic equivalent.” Annual U.S. sales of aripiprazole oral solution were $62.8 million as of June 2015, according to IMS Health.
Visit https://prd02.apsiva.net/210/GenericCategory/Aripiprazole-pi.pdf for full prescribing information.